Observational studyDiabetologia2025
One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.
Observational study in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04414280 (The Impact of Hybrid Closed-loop Insulin Delivery), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Hybrid Closed-loop Insulin Delivery (Medtronic MiniMed 670G and 780G System, Tandem t:Slim X2 Control-IQ, and Omnipod 5) on Glycemic Control and Patient-reported Outcomes in People Living With Type 1 Diabetes: a Multicenter Real-world Observational Study and Safety Study in Young Children (2-6 Years Old) in Belgium
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.Diabetes, obesity & metabolism · 2026Pooled it
- Article
- Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist.BMJ open diabetes research & care · 2026Article
- Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries.Diabetes, obesity & metabolism · 2026Article
- Rethinking control-IQ+ technology: Simple strategies for easy optimization.Diabetes, obesity & metabolism · 2026Review
- Sleep-AID: a cross-sectional analysis of subjective sleep quality, psychosocial measures and real-world glycemic outcomes in people with diabetes using automated insulin delivery systems.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Real-World Experience With Control-IQ Technology in Saudi Children With Insulin-Dependent Diabetes: A Single-Center Observational Study.Pediatric diabetes · 2026Observational
- Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology.Therapeutic advances in endocrinology and metabolism · 2026Article
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy.Expert review of medical devices · 2025Review
- Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes.Advances in therapy · 2025Article
- Impact of Automated Insulin Delivery Systems in Children and Adolescents with Type 1 Diabetes Previously Treated with Multiple Daily Injections: A Single-Center Real-World Study.Medicina (Kaunas, Lithuania) · 2025Observational
- A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Review
- Switching From Regular U-500 to Insulin Lispro U-200 in an Automated Insulin Delivery System.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
aims/hypothesisThis multicentre prospective observational cohort study aimed to evaluate real-world changes in glycaemic and person-reported outcomes after 1 year's use of Control-IQ technology in adults with type 1 diabetes.
methodsAdults who started with Control-IQ between December 2021 and December 2022 were consecutively recruited in 13 Belgian diabetes centres. Data were collected at start and after 4, 8 and 12 months. The primary endpoint was the evolution of time in range (TIR; glucose levels of 3.9-10.0 mmol/l). Data are reported as mean ± SD or least-squares mean (95% CI).
resultsA total of 473 adults were included, with a mean age of 38.5 ± 13.1 years and of whom 57.3% were female. TIR increased from 58.8% (95% CI 56.7, 60.9) at start to 70.9% (69.1, 72.8) at 12 months (p<0.001). HbA CONCLUSIONS/
interpretationOne-year use of Control-IQ was associated with better glucose management, improved diabetes-related quality of life, more treatment satisfaction, less severe hypoglycaemia and less work absenteeism in adults with type 1 diabetes.
trial registrationClinicalTrials.gov NCT04414280.
Indexed as
Identifiers
39934368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.